Pre-manifest Huntington’s disease gene-expansion carriers, gene carriers with Stage I Huntington’s disease, gene carriers with Stage II Huntington’s disease and healthy control participants:
- Female and male adults, age 20-65 years old, inclusive.
- Body Mass Index (BMI) between 19 and 35 inclusive.
- Capacity to give full informed consent in writing, and have read and signed the informed consent form (ICF).
- Are capable of complying with study procedures, including fasting and blood sampling
- Able and willing to travel to imaging PET center in Leuven, Belgium.
- Willing to comply with the use of adequate contraceptive measures.
Pre-manifest Huntington’s disease gene-expansion carriers:
- Do not have clinical diagnostic motor features of HD, defined as Unified Huntington’s Disease Rating Scale (UHDRS) Diagnostic Confidence Score < 4; and
- Have CAG expansion ≥ 40; and
- Have a CAP score > 70 (as calculated with CAP formula: AGE * (CAG – 30) / 6.49).
Gene carriers with Stage I Huntington’s disease:
- Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
- Have CAG expansion ≥ 40; and
- Have Stage I HD, defined as UHDRS Total Functional Capacity (TFC) scores between 11 and 13 inclusive.
Gene carriers with Stage II Huntington’s disease:
- Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
- Have CAG expansion ≥ 40; and Have Stage II HD, defined as UHDRS Total Functional Capacity (TFC) scores between 7 and 10 inclusive.
Healthy control participants:
- Have no known family history of HD; or
- Have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD (CAG < 36).
- Matched by age +/- 5 years.
- (Phase 1 only) under 35 years of age.